Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Multicancer screening test based on the detection of circulating non haematological proliferating atypical cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, c2002-
    • الموضوع:
      Artificial Intelligence* ; Neoplasms*; Humans
    • نبذة مختصرة :
      Background: the problem in early diagnosis of sporadic cancer is understanding the individual's risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models based on non-invasive screening tests. A tentative solution to the problem may be a cancer screening blood-based test able to discover those cell requirements triggering subclinical and clinical onset latency, at the stage when the cell disorder, i.e. atypical epithelial hyperplasia, is still in a subclinical stage of proliferative dysregulation.
      Methods: a well-established procedure to identify proliferating circulating tumor cells was deployed to measure the cell proliferation of circulating non-haematological cells which may suggest tumor pathology. Moreover, the data collected were processed by a supervised machine learning model to make the prediction.
      Results: the developed test combining circulating non-haematological cell proliferation data and artificial intelligence shows 98.8% of accuracy, 100% sensitivity, and 95% specificity.
      Conclusion: this proof of concept study demonstrates that integration of innovative non invasive methods and predictive-models can be decisive in assessing the health status of an individual, and achieve cutting-edge results in cancer prevention and management.
      (© 2024. The Author(s).)
    • References:
      J Transl Med. 2016 May 12;14(1):133. (PMID: 27176720)
      JAMA. 2020 Mar 3;323(9):863-884. (PMID: 32125402)
      Nat Rev Clin Oncol. 2022 Sep;19(9):600-612. (PMID: 35915225)
      Nat Genet. 2023 Aug;55(8):1301-1310. (PMID: 37500728)
      Acta Cytol. 2023;67(3):295-303. (PMID: 36509041)
      EBioMedicine. 2019 Aug;46:4-5. (PMID: 31399383)
      Br J Cancer. 2023 May;128(9):1636-1646. (PMID: 36737659)
      Sci Rep. 2020 Oct 28;10(1):18422. (PMID: 33116179)
      Nat Med. 2023 Dec;29(12):3044-3049. (PMID: 37973948)
      Nat Rev Cancer. 2017 Apr;17(4):239-253. (PMID: 28256574)
      Lancet Reg Health Eur. 2022 Apr 14;16:100353. (PMID: 35492962)
      Sci Rep. 2018 Apr 11;8(1):5823. (PMID: 29643468)
      Clin Chem. 2012 May;58(5):936-40. (PMID: 22205690)
      Sci Rep. 2019 Mar 11;9(1):4021. (PMID: 30858456)
      Sci Transl Med. 2021 Jan 27;13(578):. (PMID: 33504648)
    • Contributed Indexing:
      Keywords: Cancer prevention; Liquid biopsy; Multicancer diagnosis; Neural network algorithm; Non heamatological proliferating cells; Predictive model; Supervised machine learning
    • الموضوع:
      Date Created: 20240213 Date Completed: 20240215 Latest Revision: 20240228
    • الموضوع:
      20240229
    • الرقم المعرف:
      PMC10863189
    • الرقم المعرف:
      10.1186/s12943-024-01951-x
    • الرقم المعرف:
      38350884